Bacillus Subtilis (BG01-4TM) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial
Open Access
Abstract
Background: Functional gastrointestinal disorders (FGIDs) are common, difficult-to-manage conditions. Probiotics are emerging as a dietary component that influence gastrointestinal (GI) health. We conducted a double-blinded randomised controlled trial of a proprietary strain of deactivated Bacillus subtilis (BG01-4™) high in branched-chain fatty acids (BCFA) to treat self-reported FGID. Methods: Participants (n = 67) completed a four-week intervention of BG01-4™ (n = 34) or placebo (n = 33). The Gastrointestinal Symptom Rating Scale (GSRS) served as the outcome measure, collected prior to, at two weeks, and at four weeks after completion of the intervention. Results: At four weeks, one of three primary outcomes, constipation in the experimental group, was improved by 33% compared to placebo (15%); both other primary outcomes, Total GSRS and diarrhoea, were significantly improved in both the experimental and placebo groups (32%/26% and 20%/22%, respectively). The pre-planned secondary outcome, indigestion, was improved at four weeks (32%) but compared to the placebo (21%) was not significant (p = 0.079). Exploratory analysis, however, revealed that clusters for constipation (18% improvement, p < 0.001), indigestion (11% improvement, p = 0.04), and dyspepsia (10% improvement, p = 0.04) were significantly improved in the intervention group compared to the placebo. Conclusions: These initial findings suggest that in people with self-reported FGID, BG01-4™ improves specific symptoms of constipation and related GI dysfunction. Longer-term confirmatory studies for this intervention are warranted. Trial registration: This study was registered prospectively (25 October 2021) at the Australian New Zealand Clinical Trials Registry (ACTRN12621001441808p).Keywords
This publication has 50 references indexed in Scilit:
- Abdominal Bloating: Pathophysiology and TreatmentJournal of Neurogastroenterology and Motility, 2013
- Probiotics and irritable bowel syndromeWorld Journal of Gastroenterology, 2013
- Branched Chain Fatty Acids Reduce the Incidence of Necrotizing Enterocolitis and Alter Gastrointestinal Microbial Ecology in a Neonatal Rat ModelPLOS ONE, 2011
- Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel DisordersJournal of Clinical Gastroenterology, 2011
- Branched Chain Fatty Acid Content of United States Retail Cow's Milk and Implications for Dietary IntakeLipids, 2011
- Review article: endpoints used in functional dyspepsia drug therapy trialsAlimentary Pharmacology & Therapeutics, 2011
- Branched Chain Fatty Acids Are Constituents of the Normal Healthy Newborn Gastrointestinal TractPediatric Research, 2008
- Irritable bowel syndrome: a little understood organic bowel disease?The Lancet, 2002
- Well-Being and Gastrointestinal Symptoms among Patients Referred to Endoscopy Owing to Suspected Duodenal UlcerScandinavian Journal of Gastroenterology, 1995
- Quality of Life in Patients with Upper Gastrointestinal Symptoms: An Improved Evaluation of Treatment Regimens?Scandinavian Journal of Gastroenterology, 1993